A Study of Acyclovir to Help Prevent HIV Infection in People With Genital Herpes
Completed · Phase 3 · Has a placebo group
Conditions studied: HIV Infections, HIV Seronegativity, Herpes Genitalis
In brief
Genital herpes (HSV-2) is the most common cause of genital sores worldwide, and the presence of genital sores is a significant risk factor for becoming infected with HIV. This study will test the effectiveness of twice-daily dosing of acyclovir, a commonly prescribed anti-herpes drug, in preventing HIV infection in HSV-2 infected women who sleep with men (WSM) and men who sleep with men (MSM). Study hypothesis: Given that genital herpes is a significant risk factor to HIV acquisition, twice-daily HSV-2 suppressive therapy - 400 mg of acyclovir - will prevent HIV infection among high risk, HSV-2 seropositive WSM and MSM.
Key facts
- Study ID
- NCT00076232
- Run by
- National Institute of Allergy and Infectious Diseases (NIAID)
- People needed
- 3682
- Starts
- 2005-04-01
- Expected to finish
- 2007-11-01
- Last updated by the study team
- 2010-12-30
Who can join
Age: any. Sex: any. Healthy volunteers: not accepted.
Where it is running
- San Francisco Department of Public Health, AIDS Office, Research Section — San Francisco, California, United States
- New York Blood Center — New York, New York, United States
- University of Washington — Seattle, Washington, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.